BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20425315)

  • 1. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B
    Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
    Shan D; Ledbetter JA; Press OW
    Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
    Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
    Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
    Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanisms of action of rituximab in the elimination of tumor cells.
    Johnson P; Glennie M
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):3-8. PubMed ID: 12652458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
    Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
    Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines.
    Cittera E; Onofri C; D'Apolito M; Cartron G; Cazzaniga G; Zelante L; Paolucci P; Biondi A; Introna M; Golay J
    Cancer Immunol Immunother; 2005 Mar; 54(3):273-86. PubMed ID: 15449038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
    Peng W; Zhang X; Mohamed N; Inghirami G; Takeshita K; Pecora A; Nardone LL; Pincus SE; Casey LS; Spitalny GL
    Cancer Immunol Immunother; 2005 Dec; 54(12):1172-9. PubMed ID: 15846490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.
    Bobrowicz M; Kusowska A; Krawczyk M; Zhylko A; Forcados C; Slusarczyk A; Barankiewicz J; Domagala J; Kubacz M; Šmída M; Dostalova L; Marhelava K; Fidyt K; Pepek M; Baranowska I; Szumera-Cieckiewicz A; Inderberg EM; Wälchli S; Granica M; Graczyk-Jarzynka A; Majchrzak M; Poreba M; Gehlert CL; Peipp M; Firczuk M; Prochorec-Sobieszek M; Winiarska M
    Oncoimmunology; 2024; 13(1):2362454. PubMed ID: 38846084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.
    Lee SM; Min SW; Kwon HS; Bae GD; Jung JH; Park HI; Lee SH; Lim CS; Ko BJ; Lee JC; Jung ST
    Sci Rep; 2023 Oct; 13(1):18275. PubMed ID: 37880350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
    Terui Y; Sakurai T; Mishima Y; Mishima Y; Sugimura N; Sasaoka C; Kojima K; Yokoyama M; Mizunuma N; Takahashi S; Ito Y; Hatake K
    Cancer Sci; 2006 Jan; 97(1):72-9. PubMed ID: 16367924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope.
    Uchiyama S; Suzuki Y; Otake K; Yokoyama M; Ohta M; Aikawa S; Komatsu M; Sawada T; Kagami Y; Morishima Y; Fukui K
    Cancer Sci; 2010 Jan; 101(1):201-9. PubMed ID: 19930155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.
    Lv Y; Du Y; Li K; Ma X; Wang J; Du T; Ma Y; Teng Y; Tang W; Ma R; Wu J; Wu J; Feng J
    Cell Commun Signal; 2023 Jan; 21(1):16. PubMed ID: 36691066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.
    Oflazoglu E; Audoly LP
    MAbs; 2010; 2(1):14-9. PubMed ID: 20081379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
    Jeon MJ; Yu ES; Choi CW; Kim DS
    Korean J Intern Med; 2023 Nov; 38(6):893-902. PubMed ID: 37599392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.
    Griffioen M; van Egmond EH; Kester MG; Willemze R; Falkenburg JH; Heemskerk MH
    Haematologica; 2009 Sep; 94(9):1316-20. PubMed ID: 19734426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
    Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
    Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential effect of statins on rituximab immunotherapy.
    Cragg MS
    PLoS Med; 2008 Mar; 5(3):e77. PubMed ID: 18366253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.